Cure versus control: Which is the best strategy?

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Cure versus control: Which is the best strategy?"

Transcription

1 Cure versus control: Which is the best strategy? Barcelona Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

2 MULTIPLE MYELOMA Cure versus control Young patients HIGHER CR LONGER SURVIVAL DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

3 RATIONALE Young ASCT patients EFS OS Haurousseu JL et al, J Clin Oncol 2009

4 MULTIPLE MYELOMA Cure versus control Young patients HIGHER CR LONGER SURVIVAL Elderly patients HIGHER CR LONGER SURVIVAL DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

5 RATIONALE Elderly patients MP MPT 5 VMP 6 VMPT-VT 6 No Pts CR 3% 16% 24% 38% VGPR 5% 9% 26% 21% PR 52% 84% 81% 89% V= Velcade; M= Melphalan; P= Prednisone; T= Thalidomide; R= Lenalidomide

6 STUDY DESIGN Patients with newly diagnosed MM, 65 years enrolled in phase III trials : GISMM-2001 MP vs MPT, HOVON MP vs MPT, GIMEMA MM0305 VMP vs VMPT-VT Phase III MP vs MPT N=331 Phase III MP vs MPT N=344 Phase III VMP vs VMPT-VT N=511 Best response available in 1,136 patients CR N=195 VGPR N=212 PR N=397 Gay F et al, Blood Mar 17;117(11):

7 SURVIVAL ACCORDING TO RESPONSE yr: CR 91% vs VGPR 70% vs PR 67% Gay F et al, Blood Mar 17;117(11):

8 AGE OVER 75:OVERALL SURVIVAL CR 88% vs VGPR 65% vs PR 57% Gay F et al, Blood Mar 17;117(11):

9 MULTIPLE MYELOMA Cure versus control Young patients HIGHER CR Elderly patients HIGHER CR LONGER SURVIVAL Tx intensification CURE LONGER SURVIVAL DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

10 MULTIPLE MYELOMA Cure versus control Tx intensification CURE TOXICITY DISCONTINUATION DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

11 MPT and VMP Severe AEs and early discontinuation ITT Doses Grade 3-4 AEs Early Discontinuation MPT 1 Thalidomide 400 mg/d 50% 45% MPT 2 Thalidomide 100 mg/d 50% 41% VMP 3 Bortezomib 1.3mg/m 2 d1,4,8,11 91% 34% 1. Facon T, et al. Lancet. 2007; 370: Palumbo A, et al. Lancet. 2006;367: San Miguel J, et al. N Engl J Med. 2008;359:

12 VMPT-VT vs VMP: discontinuation and dose intensity Years of Age > 75 Years of Age EFS (%) VMPT- VT VMP EFS (%) VMPT-VT VMP 0.00 HR 0.51, p< HR 0.63, p= Months Months VMPT VT VMP Discontinuation from induction < 9 cycles due to AE (%) years > 75 years Median cumulative dose intensity (mg/m 2 ) years > 75 years Palumbo A, et al. Blood. 2010;116:[abstract 620]. Updated data presented at ASH 2010.

13 Patients (%) MM-015: discontinuation and dose intensity HR Log rank P = All patients MP MPR-R MPR Discontinuation from induction < 9 cycles due to AE (%) years 12 4 > 75 years 19 8 Cumulative dose intensity (%) MPR Patients (%) HR Log rank P < Time (months) years > 75 years Years of Age MP MP MPR-R MPR HR Log rank P < HR Log rank P = Time (months)

14 Lower dose regimens may benefit elderly patients Treatments that give good results in patients between 65 and 75 years of age can give poor results in patients over 75 years due to toxicity and discontinuation lower dose of conventional treatments can improve outcomes for elderly, frail patients 1 lower doses of novel agents or appropriate prophylaxis may be indicated in older patients 1,2 1. Haematological Malignancies in the Elderly Proceedings of the First International Conference; Ch4: NCCN Guidelines: Multiple Myeloma v

15

16 Lenalidomide + Dexamethasone in NDMM: ECOG Trial Study Design Lenalidomide + High-Dose Dexamethasone (RD) a Len: 25 mg/day, days 1-21 Dex: 40 mg/day, days 1-4, 9-12, (n = 223) Lenalidomide + Low-Dose Dexamethasone (Rd) Len: 25 mg/day, days 1-21 Dex: 40 mg/day, days 1, 8, 15, 22 (n = 222) 4 cycles b Transplant-eligible patients can proceed to SCT Continue therapy until disease progression Objective: to assess if a reduced dose of dexamethasone decreases toxicity while maintaining efficacy Primary endpoint: ORR after first 4 cycles a Based on the superiority of the Rd regimen, the study was stopped at a median follow-up of 12.5 months and patients in the RD arm crossed over to Rd therapy. b Every 28 days; N = 445. ECOG, Eastern Cooperative Oncology Group; NDMM, newly diagnosed multiple myeloma; ORR, overall response rate; SCT, stem cell transplant. Rajkumar SV, et al. Lancet Oncol. 2010;11:29-37.

17 Lenalidomide + Dexamethasone in NDMM: ECOG Trial Progression-Free Survival Progression-free survival was higher in the Rd arm than in the RD arm ECOG, Eastern Cooperative Oncology Group; NDMM, newly diagnosed multiple myeloma; Rd, lenalidomide, low-dose dexamethasone; RD, lenalidomide, high-dose dexamethasone. Rajkumar SV, et al. Lancet Oncol. 2010;11:29-37.

18 MULTIPLE MYELOMA Cure versus control Dose reduction and tumor control is the best strategy particularly in elderly patients or with comorbilities DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

19 Tailored therapy efficacy toxicyty DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY

Treatment results with Bortezomib in multiple myeloma

Treatment results with Bortezomib in multiple myeloma Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of

More information

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous

More information

Multiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D.

Multiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D. Multiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm,

More information

Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida

Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple

More information

Modern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review

Modern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review Modern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review Dr. Kalita Lohit kumar 1, Dr. Gogoi Pabitra Kamar 2, Dr. Sarma Umesh Ch. 3 1 MS, Assistant Professor,

More information

New Treatments in Multiple Myeloma ASS-FDA SYMPOSIUM 2015

New Treatments in Multiple Myeloma ASS-FDA SYMPOSIUM 2015 New Treatments in Multiple Myeloma ASS-FDA SYMPOSIUM 2015 S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine

More information

Considerations for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients

Considerations for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients Hello, my name is Suzanne Lentzsch. I am an associate professor of medicine at Columbia University Medical Center in New York. I am the clinical director of the Multiple Myeloma Amyloidosis Service. Today,

More information

Multiple Myeloma. New drugs and transplant: before, during and after. (Mieloma multiplo. Nuovi farmaci e trapianto: prima, durante e dopo.

Multiple Myeloma. New drugs and transplant: before, during and after. (Mieloma multiplo. Nuovi farmaci e trapianto: prima, durante e dopo. Multiple Myeloma. New drugs and transplant: before, during and after. (Mieloma multiplo. Nuovi farmaci e trapianto: prima, durante e dopo.) Benedetto Bruno Divisione di Ematologia dell'università di Torino,

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended

More information

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival

More information

ORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441

ORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441 European Journal of Haematology ISSN 0902-4441 ORIGINAL ARTICLE Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory

More information

Review of health-related quality of life data in multiple myeloma patients treated with novel agents

Review of health-related quality of life data in multiple myeloma patients treated with novel agents OPEN Leukemia (2013) 27, 1959 1969 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu REVIEW Review of health-related quality of life data in multiple myeloma patients

More information

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly

More information

2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper

2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper 248 Ivyspring International Publisher Journal of Cancer 2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper Partial Response at Completion of Bortezomib- Thalidomide-Dexamethasone (VTd) Induction

More information

Future strategies for myeloma: An overview of novel treatments In development

Future strategies for myeloma: An overview of novel treatments In development Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide

More information

AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?

AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE? AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE? *Patrizia Tosi Hematology Unit, Department of Oncology and Hematology, Infermi Hospital, Rimini, Italy *Correspondence

More information

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured

More information

Disclosures. In compliance with ACCME policy, ASH requires the following disclosures to the activity audience:

Disclosures. In compliance with ACCME policy, ASH requires the following disclosures to the activity audience: A Phase II Study of Bortezomib (Velcade ), Cyclophosphamide (Cytoxan ), Thalidomide (Thalomid ) and Dexamethasone as First- Line Therapy for Multiple Myeloma Sundar Jagannath 1, Bill Bensinger 2, Robert

More information

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing MULTIPLE MYELOMA How to treat elderly patients with multiple myeloma: combination of therapy or sequencing Antonio Palumbo 1 and Francesca Gay 1 1 Divisione di Ematologia dell Università di Torino, Azienda

More information

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma CLINICAL TRIALS AND OBSERVATIONS Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Antonio Palumbo, 1 Maria Teresa Ambrosini, 1 Giulia Benevolo, 2 Patrizia Pregno, 2 Norbert

More information

What's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D.

What's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D. What's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D. The progress being made for the treatment of multiple myeloma has resulted in a significant prolongation

More information

Multiple Myeloma. Solving a growing puzzle

Multiple Myeloma. Solving a growing puzzle Multiple Myeloma Solving a growing puzzle Disclosures Financial I wish. I eat too much. I did ask who the audience would be. Nurses and Doctors Goals 1. Understand the incidence, symptoms, and pathophysiology

More information

FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES. Updated December, 2011. Authors: Nebu Koshy, MD. Binu Nair, MD. Gerhard Hildebrandt, MD

FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES. Updated December, 2011. Authors: Nebu Koshy, MD. Binu Nair, MD. Gerhard Hildebrandt, MD FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES Updated December, 2011 Authors: Nebu Koshy, MD Binu Nair, MD Gerhard Hildebrandt, MD Reinhold Munker, MD Glenn Mills, MD Mandatory initial tests

More information

Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans

Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans C. Daniel Mullins, PhD Professor Pharmaceutical Health Services Research Department University

More information

Stem Cell Transplantation for Multiple Myeloma: Current and Future Status

Stem Cell Transplantation for Multiple Myeloma: Current and Future Status CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Stem Cell Transplantation for Multiple Myeloma: Current and Future Status Sergio Giralt 1 1 Memorial Sloan Kettering Cancer Center, New York, NY High-dose

More information

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens

More information

Blood and Marrow. Reviews A Publication of the American Society for Blood and Marrow Transplantation. Issues in Hematology, Oncology, and Immunology

Blood and Marrow. Reviews A Publication of the American Society for Blood and Marrow Transplantation. Issues in Hematology, Oncology, and Immunology Transplantation Reviews A Publication of the American Society for Transplantation Issues in Hematology, Oncology, and Immunology Volume 22 No 2 2013 Release Date July 12, 2013 In this issue INTRODUCTION

More information

New Targets and Treatments for Follicular Lymphoma. Disclosures

New Targets and Treatments for Follicular Lymphoma. Disclosures Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:

More information

Multiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases

Multiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases Multiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases Robert Vescio, MD Director Multiple Myeloma & Bone Metastases Program Samuel Oschin Comprehensive Cancer Center Cedars-Sinai

More information

NCCN Practice Guidelines in Oncology Multiple Myeloma v

NCCN Practice Guidelines in Oncology Multiple Myeloma v NCCN Practice Guidelines in Oncology Multiple Myeloma v.3.2010 Summary of the Guidelines Update National Comprehensive Cancer Network Version 3.2010. Treatments Placed in New Categories: Primary Induction

More information

Practice of Interferon Therapy

Practice of Interferon Therapy Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department

More information

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data

More information

Multiple Myeloma. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1

Multiple Myeloma. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1 Multiple Myeloma 8 th Annual Living with Myeloma Conference New Developments in Multiple Myeloma Treatment Scottsdale, AZ March 22, 2014 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville,

More information

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior - First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti

More information

MULTIPLE MYELOMA. Version Date: February, 2015

MULTIPLE MYELOMA. Version Date: February, 2015 MULTIPLE MYELOMA Version Date: February, 2015 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted approaches

More information

Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma

Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma ORIGINAL ARTICLE LONG-TERM RESULTS OF REV-DEX THERAPY FOR NEWLY DIAGNOSED MYELOMA Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

REVLIMID and IMNOVID for Multiple Myeloma

REVLIMID and IMNOVID for Multiple Myeloma REVLIMID and IMNOVID for Multiple Myeloma What is Multiple Myeloma? Multiple myeloma (MM) is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and immune suppression.

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Integrating novel agents into multiple myeloma treatment current status in Switzerland and treatment recommendations

Integrating novel agents into multiple myeloma treatment current status in Switzerland and treatment recommendations current status in Switzerland and treatment recommendations Christian Taverna a, Mario Bargetzi b, Daniel Betticher c, Jürg Gmür d, Michael Gregor e, Dominik Heim f, Urs Hess g, Nicolas Ketterer h, Erika

More information

Evaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide

Evaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide chapter 7 Evaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide A.M.W. van Marion* J.A. Auwerda* T. Lisman P. Sonneveld H.M. Lokhorst F.W.G. Leebeek

More information

European Perspective on Multiple Myeloma Treatment Strategies in 2014

European Perspective on Multiple Myeloma Treatment Strategies in 2014 European Perspective on Multiple Myeloma Treatment Strategies in 2014 HEINZ LUDWIG, a PIETER SONNEVELD, b FAITH DAVIES, c JOAN BLADÉ, d MARIO BOCCADORO, e MICHELE CAVO, f GARETH MORGAN, g JAVIER DE LA

More information

FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS

FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS ORIGINAL ARTICLE FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS Jakub Radocha, Vladimír Maisnar, Alžběta Zavřelová, Melanie Cermanová,

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Focus on the Treatment of Multiple Myeloma

Focus on the Treatment of Multiple Myeloma Focus on the Treatment of Multiple Myeloma PRINTER-FRIENDLY VERSION AT CLINICALONCOLOGY.COM SHAJI KUMAR, MD Associate Professor of Medicine Division of Hematology Mayo Clinic Rochester, Minnesota S. VINCENT

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

Laura Biganzoli Oncologia Medica Nuovo Ospedale di Prato Istituto Toscano Tumori

Laura Biganzoli Oncologia Medica Nuovo Ospedale di Prato Istituto Toscano Tumori EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nabpaclitaxel in elderly patients with advanced breast cancer Laura Biganzoli Oncologia Medica

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

MULTIPLE MYELOMA TREATMENT OVERVIEW

MULTIPLE MYELOMA TREATMENT OVERVIEW MULTIPLE MYELOMA TREATMENT OVERVIEW Sponsored by: This activity is supported by independent educational grants from Genentech BioOncology, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., and Novartis

More information

Therapie des Patienten mit rezidiviertem Multiplem Myelom

Therapie des Patienten mit rezidiviertem Multiplem Myelom DGHO 2014, Hamburg Therapie des Patienten mit rezidiviertem Multiplem Myelom Martin Gramatzki Division for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University of Kiel, Kiel,

More information

Momentum in Multiple Myeloma Treatment

Momentum in Multiple Myeloma Treatment WHITE PAPER Momentum in Multiple Myeloma Treatment Dr. Harish P. Dave, MD, MBA Dr. Ben Manderman, MD Quintiles examines promising new approaches to more effective multiple myeloma treatments. HIGH RESPONSE

More information

lenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited

lenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited Resubmission: lenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited 07 March 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular

More information

Review. Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Sumit Madan 1 & Shaji Kumar 1

Review. Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Sumit Madan 1 & Shaji Kumar 1 Review Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents Multiple myeloma is a plasma cell malignancy that typically affects older individuals, with

More information

Multiple Myeloma: Overview and Therapeutic Approaches

Multiple Myeloma: Overview and Therapeutic Approaches Multiple Myeloma: Overview and Therapeutic Approaches Presented as a Live Webinar Wednesday, August 14, 2013 and Wednesday, September 11, 2013 Planned and conducted by ASHP Advantage and supported by educational

More information

RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY

RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY *María-Victoria Mateos, Enrique M. Ocio, Verónica González, Julio Dávila University Hospital of Salamanca/IBSAL, Salamanca, Spain *Correspondence

More information

A Clinical Primer. for Managed Care Stakeholders

A Clinical Primer. for Managed Care Stakeholders reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders

More information

REVLIMID. Multiple Myeloma. Understanding. (lenalidomide) Improving Lives Finding the Cure. Cancer of the Bone Marrow

REVLIMID. Multiple Myeloma. Understanding. (lenalidomide) Improving Lives Finding the Cure. Cancer of the Bone Marrow Understanding REVLIMID (lenalidomide) A Publication of the International Myeloma Foundation Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure. Multiple

More information

Multicenter, Randomized Trial in Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years (GEM05>65)

Multicenter, Randomized Trial in Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years (GEM05>65) Multicenter, Randomized Trial in Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years (GEM05>65) MV Mateos, A Oriol, J Martínez, MT Cibeira, R de Paz, MJ Terol, J García-Laraña, E Bengoechea,

More information

What is New in Treating Multiple Myeloma? Luciano J. Costa, MD, PhD Associate Professor of Medicine Medical University of South Carolina

What is New in Treating Multiple Myeloma? Luciano J. Costa, MD, PhD Associate Professor of Medicine Medical University of South Carolina What is New in Treating Multiple Myeloma? Luciano J. Costa, MD, PhD Associate Professor of Medicine Medical University of South Carolina Objectives: To discuss the role of recently approved, novel agents

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Audience Response Question?

Audience Response Question? Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Terapia del paziente non candidato a trapianto

Terapia del paziente non candidato a trapianto Gammapatie monoclonali e mieloma multiplo Varese, 14 novembre 2011 Terapia del paziente non candidato a trapianto Luca Baldini UO Ematologia 1-CTMO 1 Università degli studi di Milano Fondazione IRCCS Cà

More information

Efficacy. Table 1. Overall Objective Response. Day 1 Day 2 Day 3 Day 4...Days 5-28. (vincristine infusion) (doxorubicin infusion)

Efficacy. Table 1. Overall Objective Response. Day 1 Day 2 Day 3 Day 4...Days 5-28. (vincristine infusion) (doxorubicin infusion) COST EFFECTIVENESS OF VS IN NEWLY DIAGNOSED MULTIPLE MYELOMA Mohamad A. Hussein, MD, 1 Mark Wildgust, PhD, 2 John Fastenau, MPH, RPh, 3 Catherine Tak Piech, MBA, 3 and the C2000-003 Study Group 1 The Cleveland

More information

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,

More information

BLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION

BLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION BLOOD RESEARCH VOLUME 48 ㆍ NUMBER 3 September 2013 ORIGINAL ARTICLE The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma

More information

Front Line Treatment of Elderly Multiple Myeloma in the Era of Novel Agents

Front Line Treatment of Elderly Multiple Myeloma in the Era of Novel Agents Front Line Treatment of Elderly Multiple Myeloma in the Era of Novel Agents The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

MULTIPLE MYELOMA Treatment Overview

MULTIPLE MYELOMA Treatment Overview MULTIPLE MYELOMA Treatment Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate

More information

Hematopoietic Stem-Cell Transplantation for Multiple Myeloma

Hematopoietic Stem-Cell Transplantation for Multiple Myeloma Hematopoietic Stem-Cell Transplantation for Multiple Myeloma Policy Number: Original Effective Date: MM.07.017 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Transplants

More information

Original Article Novel treatment paradigm for elderly patients with multiple myeloma

Original Article Novel treatment paradigm for elderly patients with multiple myeloma Am J Blood Res 2011;1(2):190-204 www.ajblood.us /ISSN: 2160-1992/AJBR1108004 Original Article Novel treatment paradigm for elderly patients with multiple myeloma Antonio Palumbo, Valeria Magarotto Myeloma

More information

LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova

LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired

More information

In multiple myeloma, the depth and maintenance of

In multiple myeloma, the depth and maintenance of Continuous therapy with lenalidomide in multiple myeloma by Nizar Bahlis, MD Abstract In multiple myeloma, the depth and maintenance of response to therapy has been shown to correlate with improved survival.

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

Bortezomib In Patients with Renal Failure. H. Ludwig I.Medizinische Abteilung, Zentrum für Onkologie und Hämatologie Wilhelminenspital, Wien

Bortezomib In Patients with Renal Failure. H. Ludwig I.Medizinische Abteilung, Zentrum für Onkologie und Hämatologie Wilhelminenspital, Wien Bortezomib In Patients with Renal Failure H. Ludwig I.Medizinische Abteilung, Zentrum für Onkologie und Hämatologie Wilhelminenspital, Wien Renal Impairment in Myeloma Severe renal failure is an important

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,

More information

pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013

pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013 pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

#EBMTLymphoma

#EBMTLymphoma 11th Educational Course of the EBMT Lymphoma Working Party on "Treatment of Malignant Lymphoma: State-of-the-Art and Role of Stem Cell Transplantation Heidelberg (Germany), September 24-26, 2015 #EBMTLymphoma

More information

Effects of bortezomib on the prognosis of the newlydiagnosed multiple myeloma patients with renal impairment

Effects of bortezomib on the prognosis of the newlydiagnosed multiple myeloma patients with renal impairment African Journal of Pharmacy and Pharmacology Vol. 6(11), pp. 793-797, 22 March, 2012 Available online at http://www.academicjournals.org/ajpp DOI: 10.5897/AJPP11.530 ISSN 1996-0816 2012 Academic Journals

More information

Understanding Revlimid

Understanding Revlimid Understanding Revlimid International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454 TheIMF@myeloma.org

More information

Advancements in Science. Future strategies for myeloma: new insights and treatments in development

Advancements in Science. Future strategies for myeloma: new insights and treatments in development Advancements in Science Future strategies for myeloma: new insights and treatments in development Dr Matthew Jenner Consultant Haematologist University Hospital Southampton NHS Foundation Trust 1 This

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Audience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information

Audience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,

More information

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease /publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Multiple. Powerful thinking advances the cure

Multiple. Powerful thinking advances the cure Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)

More information

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology Advance Access published August 16, 2013 Annals of Oncology 00: 1 5, 2013 doi:10.1093/annonc/mdt297 Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

More information

Outline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD

Outline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information